Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.40 |
| ▸ | GLB1 | P16278 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23559964 | 1.00 | BCHE (0.40) | BCHEGLB1DRD3HTR1ADRD2 | |
| SCHEMBL26406902 | 0.96 | BCHE (0.44) | BCHEDRD3HTR1ADRD2DRD1 | |
| SCHEMBL24379958 | 0.92 | DRD3 (0.41) | BCHEDRD3 | |
| SCHEMBL25925770 | 0.87 | OPRL1 (0.33) | BCHEALDH1A1 | |
| SCHEMBL25925738 | 0.87 | OPRL1 (0.33) | BCHEALDH1A1 | |
| SCHEMBL22802873 | 0.87 | BCHE (0.38) | BCHEGLB1DRD3HTR1ADRD2 | |
| SCHEMBL22793900 | 0.87 | BCHE (0.38) | BCHEGLB1DRD3HTR1ADRD2 | |
| SCHEMBL22856498 | 0.86 | CCR2 (0.41) | DRD3ALDH1A1 | |
| SCHEMBL26280371 | 0.86 | CCR2 (0.41) | DRD3ALDH1A1 | |
| SCHEMBL22906426 | 0.86 | BCHE (0.38) | BCHEGLB1DRD3HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | BCHE 1882/4885GLB1 1807/4885DRD3 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.